Metabolic Reprogramming as Therapy

Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.

TL;DR

Cancer cells rewire metabolism to support uncontrolled growth: they upregulate glycolysis (the Warburg effect), reroute amino acid and lipid flows, and reshape the local nutrient and pH environment. Therapeutically, metabolic reprogramming flips the question — can we exploit these rewired pathways to selectively starve, sensitize, or kill tumor cells (and reactivate immune attack)?Examples in clinic or trials: IDH1/2 inhibitors (ivosidenib, enasidenib), glutaminase inhibitors, asparaginase (in ALL), arginine deprivation, MAT2A/MTAP synthetic lethality. Most metabolic strategies remain research-stage; resistance via metabolic flexibility is the central challenge. Sources: [1]

1. The metabolic backdrop

Hanahan & Weinberg added "deregulating cellular energetics" to the Hallmarks of Cancer in 2011 (Hallmarks). Concrete shifts: Sources: [1]

Glycolysis upregulation even with O₂ available (Warburg effect) — see Cancer metabolism & Warburg.
Glutamine addiction — many tumors use glutamine for biosynthesis and TCA-cycle anaplerosis.
Lipid biosynthesis — fatty-acid synthase upregulation; cholesterol pathway reliance.
One-carbon metabolism — folate cycle / serine-glycine pathway hijacking; epigenetic effects via SAM.
Mitochondrial reprogramming — heterogeneous; some tumors are highly OXPHOS-dependent (especially CSCs).
Microenvironmental acidification (lactate efflux), hypoxia adaptation (HIF-1α stabilization).

These changes drive resistance to chemotherapy and immunotherapy and are themselves treatment vulnerabilities. Sources: [1]

2. Approved drugs that exploit metabolic rewiring

Drug / class	Target	Indication
Ivosidenib (AG-120)	mutant IDH1 (R132H)	AML, cholangiocarcinoma
Enasidenib (AG-221)	mutant IDH2	Relapsed/refractory AML
Vorasidenib	mutant IDH1/IDH2	Low-grade glioma (FDA 2024)
Asparaginase	extracellular L-asparagine depletion	ALL (decades-old)
Methotrexate, 5-FU, gemcitabine, pemetrexed	nucleotide / one-carbon metabolism	Many tumors (chemotherapy backbones)
Olaparib + others (PARP inhibitors)	DDR exploiting BRCA1/2-deficient metabolism	BRCA-mut breast/ovarian/prostate/pancreatic

These are real clinical wins where a metabolic vulnerability translated into a drug. Sources: [1]

3. Investigational targets

Many programs in Phase I–II:

Glutaminase inhibitors (CB-839 / telaglenastat) — block glutamine → glutamate → α-KG flow.
Arginine deprivation (ADI-PEG20) — exploits ASS1-deficient tumors (mesothelioma, melanoma, HCC).
MAT2A inhibitors / WRN helicase — synthetic lethality with MTAP loss (~15 % of cancers).
SHMT, MTHFD2, PHGDH inhibitors — one-carbon and serine pathway.
FASN, ACC, SREBP inhibitors — lipid biosynthesis.
Mitochondrial inhibitors (IACS-010759, metformin investigational repurposing) — Complex I or oxidative phosphorylation.
CPI-006, INCB001158 — adenosine/CD73 axis (immuno-metabolic).
MCT1/4 inhibitors (AZD3965) — block lactate transport.

Many programs have struggled with on-target toxicity (since normal cells share these pathways) and adaptive resistance.

4. Tumor metabolism × immunotherapy

A central modern insight: the tumor microenvironment is metabolically hostile to immune cells. Lactate, low pH, hypoxia, and amino-acid scarcity all suppress T-cell function. This makes immunometabolism a hot field: Sources: [1]

Adenosine pathway (CD73, CD39, A2A receptor) — adenosine in TME suppresses T-cells; antagonists in trials.
Tryptophan / IDO — IDO inhibitors disappointing in late-stage trials despite preclinical promise.
Arginine / glutamine — competition between tumor and immune cells.
Lactate / pH modulation — altering TME to favor T-cell function.

This is a major reason metabolic and immunotherapy strategies are increasingly co-developed.

5. Cancer stem cells and metabolism

CSCs (Stem cells & cancer) often have distinct metabolic dependencies from bulk tumor cells — typically more reliant on OXPHOS, fatty-acid oxidation, or specific antioxidant systems. This creates therapeutic openings: drugs that target CSC metabolism (e.g., bedaquiline-class, IACS-010759 in trials) might address the resistance/relapse problem that pure cytotoxics miss.

6. Resistance mechanisms

Metabolic plasticity is the field's central problem: Sources: [1]

Pathway switching — block glycolysis → tumor shifts to OXPHOS, and vice versa.
Nutrient scavenging — autophagy, macropinocytosis, lipid uptake.
Microenvironmental adaptation — recruit stromal cells to supply substrates.
Mitochondrial biogenesis upregulation — to compensate for damage.

Combination strategies blocking parallel metabolic routes are an active research direction.

7. What technologists can build

Flux balance / kinetic models (COBRA, Metabolic Atlas) to predict metabolic vulnerabilities.
Multi-omics integration with metabolomics (Metabolomics 101) for precision-metabolic targeting.
MR spectroscopy / hyperpolarized ¹³C MRI analytics for in vivo flux mapping.
Drug-response models integrating metabolic state.
Trial enrichment based on metabolic biomarkers (IDH mutation, MTAP loss, ASS1 status).

8. Brazilian context

Brazilian groups in metabolic oncology research: USP, UNICAMP, UFRJ, A.C. Camargo (cell metabolism, CSCs).
IDH-mutant glioma management (vorasidenib) is being incorporated; access via private oncology and select public referrals.
Asparaginase remains a backbone of pediatric ALL treatment in SUS through GBOP protocols.

References

Liu S, Zhang X, Wang W, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer 2024;23:261. PMID 39574178. https://doi.org/10.1186/s12943-024-02165-x
U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
American Cancer Society. https://www.cancer.org/cancer.html
Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
A.C. Camargo Cancer Center. https://accamargo.org.br
Fundação do Câncer (Brasil). https://www.cancer.org.br/
Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
ANVISA. https://www.gov.br/anvisa/pt-br

Metabolic Reprogramming as Therapy ​

TL;DR ​

1. The metabolic backdrop ​

2. Approved drugs that exploit metabolic rewiring ​

3. Investigational targets ​

4. Tumor metabolism × immunotherapy ​

5. Cancer stem cells and metabolism ​

6. Resistance mechanisms ​

7. What technologists can build ​

8. Brazilian context ​

See also ​

References ​